Você está na página 1de 25

Ranbaxy Laboratories Ltd., India.

2009 - 10

2|Page

Ranbaxy Laboratories Ltd., India.

Table of Contents

1.

Introduction ......................................................................................................................................... 4 1.1 Mission, Vission and aspirations ....................................................................................................... 5 1.2 Growth of Ranbaxy ........................................................................................................................... 6

2. 3. 4. 5. 6. 7.

Organizational Structure ...................................................................................................................... 7 Core competency ............................................................................................................................ 11 Life at Ranbaxy ................................................................................................................................. 11 Culture at Ranbaxy ............................................................................................................................ 12 Business Model.................................................................................................................................. 13 Factors leading to growth .................................................................................................................. 13 7.1. 7.2. 7.3. 7.4. 7.5. 7.6. Focus on Differentiated Products ............................................................................................... 13 R&D in Ranbaxy ........................................................................................................................ 15 First Mover Advantage............................................................................................................ 15 Information Security and Information synergy .......................................................................... 16 Acquisitions................................................................................................................................ 17 Agreements and collaboration .................................................................................................... 17

8. 9. 10. 11. 12.

Corporate Social Responsibility ........................................................................................................ 18 Decline of Ranbaxy ........................................................................................................................... 20 Analysis of the decline ................................................................................................................... 21 Weitzel and Jonssons Model of Organizational Decline .............................................................. 23 SWOT Analysis ............................................................................................................................. 24

12.1. Strengths ....................................................................................................................................... 24 12.2. Weaknesses .................................................................................................................................. 24 12.3. Opportunities ................................................................................................................................ 24 12.4. Threats .......................................................................................................................................... 24

Group A2

Organizational Theory Design and Change

3|Page

Ranbaxy Laboratories Ltd., India.

12.5. Top Competitors........................................................................................................................... 25 13. References ...................................................................................................................................... 25

Group A2

Organizational Theory Design and Change

4|Page

Ranbaxy Laboratories Ltd., India.

1. Introduction Ranbaxy was started by Ranbir Singh and Gurbax Singh in 1937 as a distributor for a Japanese company Shionogi. The name Ranbaxy is a portmanteau word from the names of its first owners Ranbir and Gurbax. Gurbax Singh had taken a loan from Bhai Mohan Singhs finance company Bhai Traders and Financiers Pvt. Ltd, but was unable to repay the money and transferred ownership of his company instead. Bhai Mohan Singh bought the company in 1952 from his cousins Ranbir Singh and Gurbax Singh. Bhai Mohan Singh started off by selling imported drugs. In 1956, India banned the import of finished pharma products and Ranbaxy opened a manufacturing plant in Okhla. That office is now with Bhai Mohan Singhs youngest son Analjit Singh (the promoter of the Max group of companies). After Bhai Mohan Singh's son Parvinder Singh joined the company in 1967, the company saw a significant transformation in its business and scale. It was Parvinders vision that Ranbaxy invest in both R&D as well as manufacturing in order to survive. In 1973, Ranbaxy went in for a public issue to bankroll the (R&D) project and raised Rs 70 lakh from the market. And in 1977, Davinder Singh Brar joined Ranbaxy. The duoParvinder Singh and Brarare widely credited with turning around Ranbaxys fortunes. Parvinders son, Malvinder Mohan Singh took over as the CEO in 2006. Both sons Malvinder Mohan Singh and Shivinder Mohan Singh sold the company to the Japanese company Daiichi Sankyo in June 2008.

Group A2

Organizational Theory Design and Change

5|Page

Ranbaxy Laboratories Ltd., India.

1.1 Mission, Vission and aspirations

In 1993, Ranbaxy adopted its Mission a goal that explained why the organization exists and what it is to be doing. Aspirations define the official goals that act as guiding principles for the organization. Ranbaxy defines above some of its terminal values which reflect a desired end state that the organization wishes to achieve.

Group A2

Organizational Theory Design and Change

6|Page

Ranbaxy Laboratories Ltd., India.

1.2 Growth of Ranbaxy


Year 1961 1973 77 85 87 88 90 91 92 93 Significance Company Incorporated * Ranbaxy goes public * Multipurpose chemical plant set up in Mohali for manufacture of APIs First JV in Lagos (Nigeria) is setup * Ranbaxy Research Foundation is established. * Stancare, Ranbaxy's second pharmaceutical marketing div. Starts functioning Production start-up at modern APIs plant at Toansa (Punjab) Toansa plant gets US FDA approval First US patent granted Doxycyline New facility at Mohali Agreement with Eli Lily of USA to set up JV in India to market Eli Lily's products * Agreement to set up JV in China - Guangzhou China Ltd * Enunciates corporate mission - to become a research based international Pharmaceutical Co. * New Research Centre at Gurgaon * Registered HQ in UK & USA * Fermentation plant Paonta Sahib is commissioned * GDR listed in Luxembourgh Stock Exchange Acquisition of Ohm Labs. Inc. US RLL crossed sales T/O of Rs 10,000 million * Exports reached all time high - Rs 5000 million Enters world's largest pharma market US with Products under its own name * Acquires Bayer's Generics business in Germany * Forays into Brazil. Largest pharma market in S America New manufacturing facility in Vietnam Ranbaxy USA crosses sales of $ 100 mn - fastest growing co. in US * Economics Times award for Corporate Excellence - The Co. of the Year 2002-03 * Ranbaxy & GSK enter into global alliance for drug discovery and dev. Acquires Aventis and starts ops in France * Elite club of Billion Dollar Cos. Launches Ops in Canada Third R&D facility in Gurgaon Acquisition in S Africa Acquires GSK Businesses in Italy & Spain Acquisition in Romania Strategic alliance with zenotech in global markets Redefines business model - Daiichi Sankyo as majority partner to create strategic combination of an Innovator & Generic Powerhouse Reconstitution of Executive leadership after Sankyo takeover

94

95 97 98 2000 2001 2003 2004 2005

2006

2008 2009

Group A2

Organizational Theory Design and Change

7|Page

Ranbaxy Laboratories Ltd., India.

2.

Organizational Structure

Shareholders

Board of Directors
Dr. Tsutomu Une Chairman Non Executive & Non Independent Director Chairman Non Executive & Dr. Anthony H. Wild Non Independent Independent Director Director Mr. Percy Shroff Non Executive & Independent Director Mr. Takashi Shoda Non Executive & Non Independent Director Mr. Atul Sobti

Chief Executive Officer &


Managing Director

Mr. Akihiro Watanabe Independent Director

Mr. Rajesh V. Shah Independent Director

Executive Committee
Mr. Ramesh L. Adige President, Corporate Affairs & Global Corporate Communications Mr. Arun Sawhney President, API GBU, Global Mr. Omesh Sethi Chief Financial Officer Mr. Dipak Chattaraj President, Corporate Development & Strategy Mr. David Briskman Chief Information Officer Dr. Sudarshan K. Arora President, R&D (Generics, NDDS & Drug Development) Dr. T G Chandrashekhar Vice President, Global Quality & Analytical Research Manufacturing & Supply Chain Mr. Bhagwat Yagnik Head Global Human Resources

Group A2

Organizational Theory Design and Change

8|Page

Ranbaxy Laboratories Ltd., India.

BOARD OF DIRECTORS Dr. Tsutomu Une Chairman Non Executive & Non independent Director. Dr. Tsutomu Une was inducted as a Director on the Board of Ranbaxy Laboratories Limited on December 19, 2008 and appointed as Chairman on May 24, 2009. Dr. Une joined Daiichi Pharmaceutical Company Limited (Daiichi), Japan in April 1970 and has held many important managerial positions. He was inducted on the Board of Daiichi in June 1999 and subsequently served as Managing Director for various functions during October 2002 to June 2006, when he was promoted as Senior Managing Director, Global Corporate Strategy of Daiichi. Dr. Une was inducted as Director in the Board of Daiichi Sankyo Company Limited in September 2005 and has been a Member of the Board, Senior Executive Officer, Global Corporate Strategy of Daiichi Sankyo since April 2007. Dr. Une is a graduate from Hokkaido University School of Veterinary Medicine and holds Ph.D. in Microbiology.

Mr. Atul Sobti Chief Executive Officer & Managing Director In his current role he is responsible for the global business operations of the Company encompassing pharmaceuticals, consumer healthcare, API, manufacturing and R&D. Prior to joining Ranbaxy, he spent seven years at Hero Honda and left them as the Executive Director, Sales, Marketing, Finance and HR. 30 years of his career spans over diverse industries such as durables, information technology, services, automobiles and now pharmaceuticals. Mr. Sobti joined Ranbaxy in October 2005, as the President, India, Middle East, Asia Pacific and the Global Consumer Healthcare business and was elevated to Chief Operating Officer in January 2007. An alumnus of the Indian Institute of Management, Ahmedabad, Mr. Sobti completed his graduation in Economics (Hons) from St. Stephens College, University of Delhi.

Group A2

Organizational Theory Design and Change

9|Page

Ranbaxy Laboratories Ltd., India.

Mr. Takashi Shoda Non Executive & Non Independent Director Mr. Takashi Shoda was inducted as a Director on the Board of Ranbaxy Laboratories Limited on December 19, 2008. Mr. Shoda graduated from Faculty of Pharmacy, Tokyo University in March 1972 and immediately joined Sankyo Company Limited, Japan (Sankyo), where he held various important positions mainly in the international operations group. In June, 2001 he was elected as Director of the Board of Sankyo and concurrently assumed the position of General Manager, International Pharmaceutical Division. He was then promoted to Managing Director in the following year and in June 2003 became its President and Representative Director. Mr. Shoda is President and Chief Executive Officer of Daiichi Sankyo Company Limited since September 28, 2005.

Dr. Anthony H. Wild Independent Director Dr. Anthony H. Wild was inducted as a Director on the Board of Ranbaxy Laboratories Limited on December 19, 2008. He is the co-founder and General Partner of BOWS Pharmaceuticals AG. Until its acquisition by Meda AB in August 2007, he was the Chairman of the Med Pointe Pharmaceuticals Inc., having served also as CEO from 2001 to 2006. MedPointe was formed around 2001 by the acquisition of the Carter-Wallace Company by MedPointe Capital Partners LLC, an investment group founded by Dr. Wild in the year 2000. Between 1995 and 2000, Dr. Wild worked with Warner-Lambert Company of Morris Plains (NJ) as the Executive Vice President and President of its Global Pharmaceuticals Sector since 1996 till its acquisition by Pfizer as part of its hostile acquisition in 2000. Mr. Wild graduated in 1968 with an Honors degree in Chemistry from University of York and also holds a Ph.D. in Physical Chemistry in 1971 from University of Cambridge.

Group A2

Organizational Theory Design and Change

10 | P a g e

Ranbaxy Laboratories Ltd., India.

Mr. Rajesh V. Shah Independent Director Mr. Rajesh V. Shah was inducted as a Director on the Board of Ranbaxy Laboratories Limited on December 19, 2008. Mr. Shah is the Co-Chairman and Managing Director of Mukand Ltd., Mumbai. He has in the past served as an Independent Director on the boards of ONGC Limited and Hindustan Petroleum Limited. He has also served as President of the CII during 1998-99 and held leadership positions in the Young Presidents Organization (YPO). Mr. Shah has completed Master of Arts from the University of Cambridge, UK, Masters in Business Administration from the University of California, Berkeley and has attended an Executive Management Programme at the Harvard Business School, USA.

Mr. Akihiro Watanabe Independent Director Mr. Akhiro Watanabe was inducted as a Director on the Board of the Ranbaxy Laboratories Limited on December 19, 2008. A founding partner of GCA and the founder of GCAs predecessor company, Global Corporate Advisory, Mr. Watanabe has over 25 years experience in providing M&A advisory services both in Japan and overseas. He has spent 20 years with KPMG primarily focusing on M&A advisory and M&A transaction related services. He is also a visiting professor at the Business School at Kobe University and Chuo University as well as at the postgraduate law school at Hitotsubashi University and a frequent speaker on industry panels related to M&A topics including cross-border transactions, MBOs and takeover defense strategies. Mr. Watanabe is a Japanese CPA and a graduate in Commerce and Accounting.

Mr. Percy Shroff Non Executive & Independent Director Mr. Percy Shroff was inducted as a Director on the Board of Ranbaxy Laboratories Limited on March 27, 2009. Mr. Shroff is a graduate in Arts from Whittier College, California. He has an experience of over 20 years in the medical field in Japan and India and was

Group A2

Organizational Theory Design and Change

11 | P a g e

Ranbaxy Laboratories Ltd., India.

instrumental in establishing the India offices as well as business operations of Elekta AB, a Swedish multinational providing advanced clinical solution. Mr. Shroff has held various managerial positions in the Elekta Group in India as well as overseas since he joined the company in 1991. In 1997, he was appointed as Managing Director - India Head of Elekta Instrument India Private Limited.

3. Core competency

4. Life at Ranbaxy

Group A2

Organizational Theory Design and Change

12 | P a g e

Ranbaxy Laboratories Ltd., India.

A career at Ranbaxy means an opportunity for ample learning & growth. It offers avenues to work across the globe alongside the finest minds. The Company offers a challenging assignment, a world class working environment, professional management, competitive salaries, and stock options along with exceptional rewards. Group Life Insurance, Medical Insurance and Pension plans are a few examples of the benefits provided to the employees and their dependents. Stock ownership is a part of the compensation for the managers early in their career at Ranbaxy: business results reflect straight away in their pay slip.

Such opportunities, defined career paths and allocation of rewards provide motivation to the managers and employees to work in the best interests of the company. The flexibility to work across regions develops the skills of the employee and keeps their motivation level and learning curve high. It minimizes the need for the employee to look out for better avenues and as such builds a long lasting team and provides stability to the human resource capital. It also, to some extent, minimizes the Agency problem. By aligning the goals of the employees with that of the companies by giving them stock options is a further act in this direction. By allowing people to work across in Ranbaxys different functions (cross- functional teams), they are empowered to direct the value creation activities necessary to complete different projects.

5. Culture at Ranbaxy Opportunities have never being a constraint for the deserving. Ranbaxy believe in employee growth that goes beyond vertical movements and change in designations. Potential and performance are the pillars of career progression at Ranbaxy. A robust development process supports this. This shows that the culture at Ranbaxy is highly organic.

Group A2

Organizational Theory Design and Change

13 | P a g e

Ranbaxy Laboratories Ltd., India.

6. Business Model

7. Factors leading to growth

The key to Ranbaxys growth lay in the strategic decisions taken by its management from time to time. These strategies specific patterns of decisions and actions helped them achieve a competitive advantage. It exemplifies how symbiotic interdependencies can be managed and harnessed for the organizations benefit, by manipulating the specific and general environmental forces. Ranbaxys main strategy to manage its environmental forces seems to be through forming strategic alliances for various products and markets. The company has followed an r-strategy i.e. the strategy of entering a new environment early, and has thus reaped the benefits of being an early entrant in new markets.

7.1.Focus on Differentiated Products The Company realized the importance of having a versatile product portfolio and thus is focusing on offering differentiated/value-added new products to the Indian masses. Ranbaxy has accelerated its pace to bring in new differentiated products in the Indian market to consolidate its leadership position.

Group A2

Organizational Theory Design and Change

14 | P a g e

Ranbaxy Laboratories Ltd., India.

Ranbaxy is building upon the practice of Related Diversification entry into a new domain that is related in some way to an organizations domain to gain a competitive advantage.

Examples 1. Rank in Therapy Segments Over the last few years, Ranbaxy has realigned its domestic operations to the needs of its target customer groups to have a more focused relationship with the doctors. This is aimed at providing customer specific quality services surpassing expectations.

By forming relationship with doctors, demonstrates that Ranbaxy manages symbiotic resource interdependencies by the way of co-optation to manage its specific environment better.

2. Entering into the Oncology Segment Since Ranbaxy did not have a significant presence in the Oncology segment, it entered into a strategic alliance with Zenotech Laboratories Ltd (Zenotech Labs) of Hyderabad, India, a company with a stronghold in this segment.

3. Strengthening Presence in the Asthma Segment Ranbaxy has entered into an In-licensing agreement with Eurodrug Laboratories, the Netherlands-based Pharma company for the Asthma product Doxophylline a Novel Xanthine Bronchodilator. It is a strategic step in the direction of expanding the product portfolio through differentiated products for the Indian market, in the post-patent era. 4. NCE Products India Focus Recently a licensing agreement with a Swissbio-pharmaceutical company, Debiopharm, was signed for the New Chemical Entity (NCE) Drug in the Gastroenterology segment.

Group A2

Organizational Theory Design and Change

15 | P a g e

Ranbaxy Laboratories Ltd., India.

5. Strengthening Product Basket in New Markets In Canada, soon after the launch of its products in 2005, Ranbaxy is further expanding its product portfolio through in-licensing and has already emerged as a pioneer in this area. In mid 2006, Ranbaxy Pharmaceuticals Canada Inc (RPCI) and Janssen-Ortho Inc (JOI) entered into a licensing and supply agreement for a generic version of Risperidone compressed tablets, sold underRanbaxys label, Ran Risperidone.

In-licensing agreement demonstrates that Ranbaxy makes use of the informal strategy of long term contracts to manage its resource interdependencies.

7.2. R&D in Ranbaxy NDDR A Separate Entity Decentralization Ranbaxy received an in-principle approval from the Board of Directors to de-merge its Drug Discovery Research (DDR) operation. This is a significant step in creating an independent pathway for DDR with dedicated resources and enhanced focus for long-term value building. Ranbaxy's state-of-the-art research infrastructure and scientific talent pool can be more effectively leveraged through an independent vehicle that better aligns assets with priorities to accelerate the company's drug discovery programs. The resulting operational freedom and flexibility will also help to open up new growth opportunities, while providing a platform for increased collaboration.

By the way of decentralization of NDDR, Ranbaxy has promoted flexibility and responsiveness by allowing the research department to make on the spot decisions. Ranbaxy practices division of labor and specialization by allocating dedicated resources and creating scientific talent pool to DDR. The core competency of DDR is to discover new drugs.

7.3. First Mover Advantage Ranbaxy saw a great business opportunity in Japan, the worlds second largest pharma market, and hence entered the market in the year 2002 through a strategic alliance with a mid sized research pharmaceutical company, Nippon Chemiphar Co, Ltd (NC) of Japan. Ranbaxy acquired a 10% equity

Group A2

Organizational Theory Design and Change

16 | P a g e

Ranbaxy Laboratories Ltd., India.

stake in its generic subsidiary Nihon Pharmaceutical Industry Co, Ltd (NPI). The company further consolidated its presence in Japan by increasing its equity stake in the NPI, from 10% to 50% in 2006 and NPI, thus, became a 50:50 joint venture (JV) between Ranbaxy and NC.

Ranbaxy

7.4. Information Security and Information synergy Since early 2006, Information Security (Infosec) has been a priority at Ranbaxy. Dr. Malvinder Mohan Singh, CEO and MD, Ranbaxy, took the lead to introduce. Operation Safed Sagar an initiative targeted at protecting the companys information assets. The program is focused on bringing behavioral change in people, sensitizing them to the importance of Information Security.

A policy framework called the Information Security Management System (ISMS) has been introduced and Standard Operating Procedures (SOPs) laid down. A verification and validation framework has been formulated in the ISMS to ensure sustenance of this initiative and eventual assimilation into the Ranbaxy way. The sensitization process started through a well-crafted communication program highlighting the risks and the appropriate behavior. Specific policies and procedures have been introduced. Through concerted efforts of various teams involved in the project, Ranbaxy employees have gradually understood the importance of Information Security as the rule of CIA, which is Confidentiality, Integrity and Availability.

Group A2

Organizational Theory Design and Change

17 | P a g e

Ranbaxy Laboratories Ltd., India.

By using Information security Ranbaxy has demonstrated that is uses IT To make critical information accessible to employees. To facilitate beliefs norms and values of Ranbaxy. To enhance motivational effects of cultural values.

7.5.Acquisitions Acquisitions in a row

June 2005 Efarmes in Spain March 2006 Senetek in the US March 2006 Allen in Italy March 2006 Terapia inRomania March 2006 Ethimed in Belgium July 2006 Mundogen in Spain Sep 2006 Cardinal Drugs in India Dec 2006 Be-Tabs in South Africa

In the year of 2007 alone, Ranbaxy made an acquisition of 13 established and well recognized brands of the dermatology segment from Bristol-Myers Squibb in the US.

Thus Ranbaxy has aggressively adopted merger and takeover strategy for growth in newer markets.

7.6.Agreements and collaboration 7.6.1. Agreement with GSK Extended Ranbaxy extended its strategic R&D alliance with GlaxoSmithKline (GSK), established in 2003, to provide Ranbaxy expanded drug development responsibilities and further financial opportunities. Ranbaxys role, which was to conduct the optimization chemistry required to progress drug leads to the stage of candidate selection, enlarges to advance leads beyond candidate selection, to completion of

Group A2

Organizational Theory Design and Change

18 | P a g e

Ranbaxy Laboratories Ltd., India.

clinical proof of concept. GSK thereafter will conduct further clinical development for each program and take resulting products through the regulatory approval process to final commercialization.

By forming strategic alliance with its competitor, GSK, Ranbaxy has demonstrated that it uses strategic alliance to manage its competitive interdependencies.

7.6.2. Collaborating with DST In another development, Ranbaxy entered into a collaborative agreement with the Department of Science & Technology (DST), Government of India, in the area of New Drug Discovery Research (NDDR). Under the agreement, DST will provide financial support by way of soft loans to Ranbaxy, for two NDDR programs in the therapeutic areas of Anti-infectives and Inflammation. The funding will enable Ranbaxy to conduct the preclinical toxicity studies/safety studies of the Company's NCEs in these areas and take the molecules up to human Phase-I clinical trials.

On the basis of its strong fundamentals of innovation, entrepreneurship and aggressive marketing, Ranbaxy has carved a formidable position at home and a growing footprint in the global pharma market. The Company has displayed all the qualities of a nimble, agile and a dynamic organization that has made balanced and strategic alliances in the developed as well as the emerging markets. The company has been able to tackle many of the environmental uncertainties by way of collaboration, innovation and alliances.

8. Corporate Social Responsibility An essential component of Ranbaxys corporate social responsibility is to take care of the community. Based on the theme Health for All, Ranbaxy set up Ranbaxy Rural Development Trust in 1978; later re-christened as Ranbaxy Community Health Care Society (RCHS) in 1994.

Group A2

Organizational Theory Design and Change

19 | P a g e

Ranbaxy Laboratories Ltd., India.

Provides a blend of curative, preventive and health promoting services amply supported by laboratory services covering areas of maternal child health, family planning, adolescent health, reproductive health and education.

AIDS awareness and counselling is also a priority component of the programme. Established very meaningful and useful partnerships with the Government, Medical Colleges, NGOs , Educational Institutions, Confederation of Indian Industry (CII) and other likeminded agencies which has helped RCHS to broaden its scope of services.

Group A2

Organizational Theory Design and Change

20 | P a g e

Ranbaxy Laboratories Ltd., India.

9. Decline of Ranbaxy The problems at Ranbaxy started with the sudden resignation of its CEO Mr. D.S Brar in 2004, under whose leadership, Ranbaxy had witnessed some of its best years. Ranbaxy had grown rapidly in the late 1990s and the early 2000s. Its revenue grew from Rs.1, 560 crore in 1999 to Rs.3, 614 crore in 2004. The company became a regular in the list of top 10 companies on the Bombay Stock Exchange (BSE) in terms of market capitalization. Mr. Brar had long been involved in the progress of the company, and his resignation, under unpleasant and unclear terms raised apprehensions among the share holders. Mr.D.S Brar was replaced by Mr. Brian Tempest, who had previously been regional director (Europe, Commonwealth of independent states and Africa), but was however just warming the seat for the next CEO Dr.Malvinder Singh who was just 33 yrs old. In September, 2008 the U.S. Food and Drug Administration (FDA) banned imports of more than 30 generic drugs made in India by Ranbaxy Laboratories Ltd. In banning the generic drugs importation, the FDA cited safety concerns over Ranbaxys production practices at two facilities, namely, Dewas and Paonta Sahib. However, the problems at the Ranbaxy facilities relate to the audit of the firms drug manufacturing processes, and not to the specific failure of any Ranbaxy product to meet its required specifications or to reports of human illness due to a manufacturing problem with Ranbaxy products. Ranbaxy is also the focus of a separate criminal investigation into whether it submitted fraudulent data to the FDA that allowed sale of substandard drugs. The import ban affects generic versions of several popular medicines, including the anti-cholesterol drug Zocor; Acyclovir, which treats herpes; the heartburn pill Zantac; and AIDS drugs. Because these drugs can be supplied by other generic drug manufacturers, the FDA does not expect a medicine shortage. In light of all these developments, Ranbaxys Quarterly showed dismal returns. In the three months ended 31 December 2008, the firm, reported a net loss of Rs.680 crores, compared with a net profit of Rs.188 crores in year-ago quarter. The company was acquired by Japans Daiichi Sankyo Co. Ltd in November 2008. The CEO Dr. Malvinder Singh attributed the unprecedented forex volatility following unforeseen global financial crisis and almost 25% dollar-rupee movement for the losses. In the previous quarter, Ranbaxy had lost Rs.395 crores on account of a loss on currency hedges and a one-time inventory writedown caused by the ban imposed in September by the US Food and Drugs

Group A2

Organizational Theory Design and Change

21 | P a g e

Ranbaxy Laboratories Ltd., India.

Administration (FDA) on products made at its two plants in Dewas, Madhya Pradesh, and Paonta Sahib, Himachal Pradesh. The profit margin analysis of the quarters is shown below:

Profit
800 600 400 200 0 -200 -400 -600 -800 -1000 -1200 2006 2007 2008 2009 Profit

10. Analysis of the decline 1) Ethical stance taken by the organization and the behavior of top managers strongly influences the organizational culture. As the company received warnings for submitting improper documents and falsification of documents it exposes lack of ethical culture in the organization, in case of Ranbaxy, failure to come out with sufficient justification even after receiving several warning letters exposes the fact that a ethical stance was not taken by the organization.

As we know developing a good reputation reduces transaction cost, i.e. cost of interacting with external environment, as FDA issued warning letters to Ranbaxy it led to the fall of reputation of the company. This resulted in sudden decline of stock prices which led to huge losses for the company in the fourth quarter of 2008.

2) The other major factor which led to the decline was the growth in the organization was influenced by kinship more than the technical competence and the efficiency. Mr. Brar was one

Group A2

Organizational Theory Design and Change

22 | P a g e

Ranbaxy Laboratories Ltd., India.

of the most successful president of Ranbaxy. After he had taken over from Mr. Parvinder Singh, Ranbaxy had grown from strength to strength with increasing market shares and Entry in to new markets, but his resignation under dubious circumstances followed by a brief transition period tenure of Mr. Brian Tempest and appointment of Dr. Malvinder Singh as the CEO emphasized that importance was given more to kinship rather than effectiveness of the person. If the family members do not have the strategic and organizational skills, it is better to hand over the complete running of the company to professional managers. In fact, the Ranbaxy story is one where such an event did happen. Yet, family interference and control got the better of this process and the case is a classic one of failure of transition to professional management. This emphasizes Webers second principle of bureaucracy, which states that if in an organization, family relationships are given priority rather than technical competence; it can be harmful for the growth of the organization, which is evident in this case. 3) As Ranbaxy grew and extended its operations into many countries and other variety of drugs the complexity of the external environment increased and it was not an easy task to have control over the external environment, the changes in external environment had a great influence on the decline of Ranbaxy for example a) Increase in competition for generic drugs and developed countries increasing the life cycle of patented drugs which resulted in decrease in demand for generic drugs. b) Increased regulation on generic drugs in the developed countries like USA which led to FDA imposing regulations on Ranbaxy, this increased stringent measures had a severe effect on several drugs manufactured by Ranbaxy. The fluctuation in value of dollar was also a major factor, due to decline in dollar value the company which had invested money in terms of dollars suddenly had to encounter decrease in its cash balance. These factors signify how interconnectivity between forces in the external environment increases complexity. As the regulations were imposed by FDA, the stock prices fell so it was very difficult to control the external environment.

Group A2

Organizational Theory Design and Change

23 | P a g e

Ranbaxy Laboratories Ltd., India.

This led to lack of control of Ranbaxy over its external environment and the companys top management was not able to device strategies to control external environment which finally led to Acquisition of Ranbaxy by Daaichi, Japan based Drug manufacturer

11. Weitzel and Jonssons Model of Organizational Decline Stage 1: Blinded In this stage, the organization is unable to recognize the internal or external problems that threaten their long term survival. In the case of Ranbaxy, the management failed to recognize the threat in the form Of the stringent regulations governing the entry of generic drugs in developed countries like USA etc.This led to them receiving warning letters by FDA, early in 2006, for not complying with their regulations. Stage 2: Inaction Despite receiving a warning letter in January of 2006 and tabulating a response in which corrections to the stability data previously submitted to the agency in several abbreviated new drug applications (ANDAs) were included. It also included corrected stability test reports for various medicines, and showed instances where stability test dates that previously had been submitted to the applications were false. In some cases stability testing was conducted several months later than the dates reported in the applications. However the management failed to learn the lesson and did not implement the changes in the process to ensure proper documentation of all the processes involved which led to auditing problems in checks by FDA in 2008. Prompt action at this stage by management would have prevented the decline. Stage 3: Crisis The company faced FDA import bans on various products manufactured at two of its facilities in India leading to a fall in the value of its share. The company faces huge losses to the tune of 1044 crores in 2008.This also precipitated a change in the management of the company by the parent company daaichi sankyo. This essentially forms the effective reorganization needed to prevent the decline.

Group A2

Organizational Theory Design and Change

24 | P a g e

Ranbaxy Laboratories Ltd., India.

12. SWOT Analysis 12.1. Strengths 1. Strategic Alliances GSK and Merck. 2. Differentiated Product Offering Generics, Branded Gx, Branded, OTC. Broad product portfolio imparting revenue stability. 3. Patents. 4. Strong presence in diverse geographies insulating business risks. 5. Aggressive Marketing. 6. Manufacturing Efficiencies Labour, Infrastructure and Global Quality Standards. 7. R&D capabilities skilled scientist pool, research across Generics as well as Innovative Research (NCE, NDDS, Niche FTF), and Process Chemistry Expertise. 8. Low cost innovation and high quality product flow. 9. Strong CSR programs contributing to a positive reputation in the industry. 12.2. Weaknesses 1. High Cost structure related to manufacturing, R&D and distribution. 2. Lack of ethical culture, proven when Ranbaxy submitted improper and falsified documents to USFDA. 3. Legal and Compliance issues with its manufacturing facilities at Dewas and Paonta Sahib in India. 4. Tarnishing reputation in the industry because of the above two issues. 5. Nepotism in the organization high degree of family interference and control. 12.3. Opportunities 1. Untapped high-growth emerging markets. 2. Ageing world population can act as a fundamental growth driver by providing increase in demand for medicines. 3. Possible leverage on Daiichi Sankhyos strengths. 12.4. Threats 1. High entry barriers technology and resource intensive. 2. Productivity under pressure saturated developed markets.

Group A2

Organizational Theory Design and Change

25 | P a g e

Ranbaxy Laboratories Ltd., India.

3. Disruptive Technologies challenging established portfolios. 4. Increased regulations on Generic Drugs in developed countries like USA. 5. Unpredictable dollar rate fluctuation.

12.5. Top Competitors The following companies are the major competitors of Ranbaxy Laboratories Limited 1. Dr. Reddy's Laboratories Limited 2. Abbott India 3. Morepen Laboratories 4. Kopran 5. Sun Pharmaceuticals Industries Ltd 6. Nicholas Piramal India Ltd 7. Novartis India Limited 8. GlaxoSmithKline Pharmaceuticals (India) Limited 9. IPCA Laboratories Ltd.

13. References Ranbaxy Annual Report Ranbaxy World http://www.ranbaxy.com http://www.livemint.com http://www.thehindubusinessline.com http://www.dnaindia.com

Group A2

Organizational Theory Design and Change

Você também pode gostar